In collaboration with:

Under the auspices of:

Useful links

• 
  GEHT - Le site Francophone de l'Hémostase

Preliminary Program

Thursday, June 19, 2008

16:00-17:30 SESSION 1 “Introductory lectures”

Chairpersons: Marco Cattaneo (Milano, Italy)
Christian Gachet (Strasbourg, France)

Update on P2 receptors
Jean Marie Boeynaems (Bruxelles, Belgium)

Platelet formation
John H. Hartwig (Boston, USA)

17:45-19:45 SESSION 2 “New players in platelet thrombus formation”

Chairpersons: John Hartwig (Boston, USA)
Fabiola Sinigaglia (Novara, Italy)

CD36, oxidative stress and platelet hyperreactivity
Eugene A. Podrez (Cleveland, USA)

Platelet tissue factor
Marina Camera (Milano, Italy)

Novel interactions that regulate thrombus growth and stability
Skip Brass (Philadelphia, USA)

The role of novel platelet glycoproteins receptors in regulating platelet activation
Steve Watson (Birmingham, UK)

Friday, June 20, 2008

08:00-10:00 SESSION 3 “Platelets and inflammation“

Chairpersons: Carlo Balduini (Pavia, Italy)
Steve Watson (Birmingham, UK)

Platelets, inflammation and atherosclerosis
Meinrad Gawaz (Tübingen, Germany)

P2Y1/atherosclerosis
Béatrice Hechler (Strasbourg, France)

Platelets, inflammation and acute coronary syndromes
Attilio Maseri (Firenze, Italy)

P2Y12 and inflammation
Pamela Conley (San Francisco, USA)

The anti-atherothrombotic properties of the TP-receptor antagonist Triplion
Alain Rupin (Paris, France)

10:30-12:30 SESSION 4 “Laboratory monitoring of antiplatelet drug treatment”

Chairpersons: Giovanni de Gaetano (Campobasso, Italy)
Meinrad Gawaz (Tübingen, Germany)

Variability in response to antiplatelet agents: where are we standing?
Bianca Rocca (Roma, Italy)

Is there a need for monitoring antiplatelet drug treatment?
Alan Michelson (Worcester, USA)

Is there an identifiable appropriate level of inhibition of platelet function by antiplatelet agents during PCI?
Jean-Philippe Collet (France)

Is there an identifiable appropriate level of inhibition of platelet function by antiplatelet agents for long-term treatment?
Maddalena Lettino (Pavia, Italy)

12:30-13:00 Oral Communications

13:00-16:00 Free time

16:00-18:30 SESSION 5 “Laboratory methods potentially useful for monitoring antiplatelet drug treatment”

Chairpersons: Vincenzo Toschi (Milano, Italy)
Alan Michelson (Worcester, USA)

IMPACT
David Varon (Tel Aviv, Israel)

ISTH survey on light transmission aggregometry
Marco Cattaneo (Milano, Italy)

Verify-Now
Rosanna Abbate (Firenze, Italy)

PFA-100
Ulrich Walter (Würzburg, Germany)

Thrombovision
Edward Teitel (Houston, USA)

PlaCor PRT
Bill Haworth (Minneapolis, USA)

VASP
Christian Gachet (Strasbourg, France)

18:45-19:45 Oral Communications

Saturday, June 21, 2008

08:30-11:00 SESSION 6 “New drugs, new RCT”

Chairpersons: Maddalena Lettino (Pavia, Italy)
Pierangelica Merlini (Milano, Italy)

Prasugrel: pharmakokinetics, pharmakodynamics, planned and ongoing RCT
Joseph Jakubowsky (Indianapolis, USA)

Prasugrel in the treatment of patients with ACS: the TRITON-TIM 38 trial
Stefano De Servi (Legnano, Italy)

AZD6140: pharmakokinetics and pharmakodynamics and planned and ongoing RCT
Hans van Giezen (Mölndal, Sweden)

Cangrelor: pharmakokinetics and pharmakodynamics and planned and ongoing RCT
Robert Storey (Sheffield, UK)

Clopidogrel: evolving knowledge and clinical evidence in atherothrombotic patients
Jean-Philippe Collet (France)

11:30-13:00 Oral Communications

 

download

download the pdf version: program.